Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ITR Integra Resources	C$2.09 -1.9%	C$2.29	C$1.10 ▼ C$2.68	C$247.01M	1.37	447,695 shs	256,171 shs
NSR Neustar, Inc. Neustar, Inc. Cla	$7.76	$0.00	$21.10 ▼ $34.40	$477.94M	N/A	13,059 shs	N/A
PPTA Perpetua Resources	$12.99 -3.2%	$14.10	$5.01 ▼ $17.96	$960.11M	0.02	865,408 shs	3.82 million shs
SLS Galena Biopharma	$1.54 -1.9%	$1.57	$0.77 ▼ $2.12	$156.65M	2.25	1.58 million shs	3.17 million shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ITR Integra Resources	-1.88%	-6.70%	-2.79%	+19.43%	+55.97%
NSR Neustar, Inc. Neustar, Inc. Cla	0.00%	0.00%	0.00%	0.00%	0.00%
PPTA Perpetua Resources	-3.20%	+1.17%	-4.90%	+15.98%	+89.64%
SLS Galena Biopharma	-1.91%	-7.23%	-9.41%	+28.33%	+45.28%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ITR Integra Resources	1.411 of 5 stars	3.5	0.0	0.0	0.0	0.0	2.5	0.0
NSR Neustar, Inc. Neustar, Inc. Cla	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
PPTA Perpetua Resources	2.8619 of 5 stars	3.6	1.0	0.0	0.0	3.1	3.3	0.6
SLS Galena Biopharma	0.5711 of 5 stars	0.0	1.0	0.0	0.0	3.0	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ITR Integra Resources	3.00	Buy	C$4.31	106.34% Upside
NSR Neustar, Inc. Neustar, Inc. Cla	0.00	N/A	N/A	N/A
PPTA Perpetua Resources	3.20	Buy	$21.17	62.95% Upside
SLS Galena Biopharma	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest ITR, PPTA, SLS, and NSR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/18/2025	PPTA Perpetua Resources	National Bankshares Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform
6/18/2025	PPTA Perpetua Resources	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$16.00 ➝ $17.00
6/17/2025	PPTA Perpetua Resources	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$27.50
5/13/2025	PPTA Perpetua Resources	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$28.00 ➝ $27.50
4/21/2025	ITR Integra Resources	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target		C$4.00 ➝ C$4.50
4/4/2025	ITR Integra Resources	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target		C$3.25 ➝ C$3.75
4/2/2025	PPTA Perpetua Resources	National Bankshares Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform
3/21/2025	PPTA Perpetua Resources	National Bank Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
3/21/2025	PPTA Perpetua Resources	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$25.00 ➝ $28.00

(Data available from 6/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ITR Integra Resources	N/A	N/A	C$0.61 per share	3.41	C$0.45 per share	N/A
NSR Neustar, Inc. Neustar, Inc. Cla	$27.15M	17.60	$0.19 per share	41.83	$4.72 per share	1.64
PPTA Perpetua Resources	N/A	N/A	N/A	N/A	$1.55 per share	N/A
SLS Galena Biopharma	$1M	153.66	N/A	N/A	$0.13 per share	11.85

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ITR Integra Resources	-C$40.04M	-C$0.48	N/A	∞	N/A	N/A	-63.49%	-17.95%	N/A
NSR Neustar, Inc. Neustar, Inc. Cla	-$1.68M	$0.35	22.17	77.60	N/A	3.67%	-0.47%	-0.38%	N/A
PPTA Perpetua Resources	-$14.48M	-$0.29	N/A	N/A	N/A	N/A	-22.11%	-19.91%	8/8/2025 (Estimated)
SLS Galena Biopharma	-$30.88M	-$0.38	N/A	N/A	N/A	N/A	-193.67%	-113.02%	8/12/2025 (Estimated)

Latest ITR, PPTA, SLS, and NSR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
5/13/2025	Q1 2025	SLS Galena Biopharma	-$0.1067	-$0.07	+$0.0367	-$0.07	N/A	N/A
5/9/2025	Q1 2025	PPTA Perpetua Resources	-$0.05	-$0.12	-$0.07	-$0.12	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ITR Integra Resources	N/A	N/A	N/A	N/A	N/A
NSR Neustar, Inc. Neustar, Inc. Cla	$0.16	2.06%	N/A	45.71%	N/A
PPTA Perpetua Resources	N/A	N/A	N/A	N/A	N/A
SLS Galena Biopharma	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ITR Integra Resources	35.54	0.82	1.49
NSR Neustar, Inc. Neustar, Inc. Cla	0.13	1.73	1.73
PPTA Perpetua Resources	N/A	5.95	5.95
SLS Galena Biopharma	N/A	4.64	4.64

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ITR Integra Resources	26.52%
NSR Neustar, Inc. Neustar, Inc. Cla	1.49%
PPTA Perpetua Resources	70.07%
SLS Galena Biopharma	17.38%

Insider Ownership

Company	Insider Ownership
ITR Integra Resources	17.78%
NSR Neustar, Inc. Neustar, Inc. Cla	N/A
PPTA Perpetua Resources	1.50%
SLS Galena Biopharma	1.40%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ITR Integra Resources	41	118.19 million	N/A	Not Optionable
NSR Neustar, Inc. Neustar, Inc. Cla	N/A	61.59 million	N/A	Not Optionable
PPTA Perpetua Resources	30	71.54 million	70.47 million	Optionable
SLS Galena Biopharma	10	99.78 million	98.38 million	Not Optionable

ITR, PPTA, SLS, and NSR Headlines

Recent News About These Companies

Sellas Life Sciences: Tons Of Completed Studies

June 17, 2025 | seekingalpha.com

SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) Sees Large Increase in Short Interest

June 16, 2025 | marketbeat.com

Nostrand Robert L. Van Purchases 10,000 Shares of SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) Stock

June 14, 2025 | insidertrades.com

Nostrand Robert L. Van Acquires 10,000 Shares of SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) Stock

June 13, 2025 | marketbeat.com

SELLAS Life Sciences Expands Scientific Advisory Board with Addition of Two World-Renowned Hematology and Oncology Experts

June 5, 2025 | globenewswire.com

SELLAS Life Sciences Presents Preclinical Data on SLS009 as a Targeted Therapy for ASXL1 Mutated Colorectal Cancer at ASCO 2025

June 4, 2025 | nasdaq.com

Insider Buying: SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) Director Purchases 20,000 Shares of Stock

June 3, 2025 | marketbeat.com

SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) Director Jane Wasman Buys 20,000 Shares

June 3, 2025 | insidertrades.com

SELLAS Presents Preclinical Efficacy of SLS009 in ASXL1 Mutated Colorectal Cancer at 2025 ASCO Annual Meeting

June 2, 2025 | globenewswire.com

594,919 Shares in SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) Bought by Brooklyn FI LLC

May 28, 2025 | marketbeat.com

SELLAS Life Sciences to Participate in Fireside Chat at the A.G.P. Virtual Healthcare Company Showcase

May 20, 2025 | globenewswire.com

SELLAS Life Sciences Group, Inc. Common Stock

May 16, 2025 | fxempire.com

Sellas doses first paediatric subject with AML in Phase II trial of SLS009

May 16, 2025 | msn.com

SELLAS Life Sciences Group, Inc.: SELLAS Life Sciences Announces First Pediatric AML Patient Dosed in the Ongoing Phase 2 Trial of SLS009 r/r AML

May 15, 2025 | finanznachrichten.de

SELLAS Life Sciences Announces First Pediatric AML Patient Dosed in the Ongoing Phase 2 Trial of SLS009 r/r AML

May 15, 2025 | globenewswire.com

SELLAS Life Sciences Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 13, 2025 | globenewswire.com

SELLAS Life Sciences Group, Inc. Presents Promising Preclinical Data on SLS009 for TP53 Mutated Acute Myeloid Leukemia at AACR 2025

April 28, 2025 | quiverquant.com

SELLAS Unveils Breakthrough Preclinical Data Highlighting Efficacy of SLS009 in TP53 Mutated AML at the 2025 AACR Conference

April 28, 2025 | globenewswire.com

Why SELLAS Life Sciences Group, Inc.’s (SLS) Stock Is Up 8.95%

April 26, 2025 | aaii.com

SELLAS Life Sciences Group, Inc. to Present Preclinical Efficacy Data for SLS009 in ASXL1 Mutated Colorectal Cancer at ASCO 2025 Annual Meeting

April 23, 2025 | quiverquant.com

SELLAS to Present at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

April 23, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ITR, PPTA, SLS, and NSR Company Descriptions

Integra Resources CVE:ITR

C$2.09 -0.04 (-1.88%)

As of 06/20/2025 04:00 PM Eastern

Integra Resources Corp., a precious metals exploration and development company, engages in the acquisition, exploration, and development of mineral properties in the Great Basin of the Western United States. The company explores for gold and silver deposits. It primarily focuses on developing DeLamar Project located in southwestern Idaho; and the Wildcat and Mountain View Projects located in western Nevada. It also holds a portfolio of early-stage exploration projects in Idaho, Nevada, and Arizona. The company was formerly known as Mag Copper Limited and changed its name to Integra Resources Corp. in August 2017. Integra Resources Corp. was incorporated in 1997 and is headquartered in Vancouver, Canada.

Neustar, Inc. Neustar, Inc. Cla NYSE:NSR

NeuStar, Inc. is a global information services provider. The Company's cloud-based platforms and differentiated data sets offer informative, real-time analytics, which enable clients to make actionable, data-driven decisions. It provides chief marketing officers a suite of services to plan their media spends, identify and locate desired customers, invest in marketing campaigns, deliver relevant offers and measure the performance of these activities. Security professionals use the Company's solutions to maximize Web performance and protect against malicious attacks. It enables the exchange of essential operating information across multiple carriers to provision and manage services, assisting clients with order processing and routing of customer inquiries. The Company's services include marketing services, security services, data services and number portability administration center (NPAC) services.

Perpetua Resources NASDAQ:PPTA

$12.99 -0.43 (-3.20%)

Closing price 06/20/2025 04:00 PM Eastern

Extended Trading

$13.17 +0.18 (+1.39%)

As of 06/20/2025 07:59 PM Eastern

Perpetua Resources Corp. engages in the exploration and development of mineral properties in the United States. The company primarily explores for gold, silver, and antimony deposits. Its principal asset is the 100% owned Stibnite Gold project, which includes 1,672 unpatented lode claims, mill sites, and patented land holdings covering an area of approximately 11,548 hectares located in Valley County, Idaho. The company was formerly known as Midas Gold Corp. and changed its name to Perpetua Resources Corp. in February 2021. Perpetua Resources Corp. was incorporated in 2011 and is headquartered in Boise, Idaho.

Galena Biopharma NASDAQ:SLS

$1.54 -0.03 (-1.91%)

Closing price 06/20/2025 04:00 PM Eastern

Extended Trading

$1.54 +0.00 (+0.06%)

As of 06/20/2025 07:55 PM Eastern

SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase 3 clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; and GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009, a highly selective small molecule CDK9 inhibitor, currently under Phase 1 clinical trials. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time